Former Biogen CEO Scangos to be BIO'S COVID-19 czar: report

George Scangos
George Scangos (Vir)

The chief executive of infectious disease biotech Vir, George Scangos, has been handed the reins to lead the biotech industry’s battle against the novel coronavirus COVID-19.

Scangos is the former CEO of Biogen who now leads a biotech that, in partnership with China’s WuXi Biologics, is looking to help make a treatment for the disease (and also saw its shares shoot up on the news).

U.S. Vice President Mike Pence is heading up the government’s response to the coronavirus, but Scangos has been tapped by BIO to help lead its efforts to research therapeutics and diagnostics to stave off the spread of the virus.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

“The role is still evolving, but it is clear someone needs to pick up the reins. It is only natural for us here at Vir to take on a leadership role,” Scangos said in an interview with Reuters.

This comes as the first deaths from the disease were registered in the U.S. over the weekend. The country is now stepping up its response to the disease with wider testing, which had been fairly limited over the past two months.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.